Iodine-123

Last updated
Iodine-123, 123I
General
Symbol 123I
Names iodine-123, 123I, I-123,
radioiodine
Protons (Z)53
Neutrons (N)70
Nuclide data
Natural abundance 0
Half-life (t1/2)13.22 h
Isotope mass 122.905589(4) Da
Parent isotopes 123Xe
Decay products 123Te
Decay modes
Decay mode Decay energy (MeV)
electron capture0.159 (159 keV)
Isotopes of iodine
Complete table of nuclides

Iodine-123 (123I) is a radioactive isotope of iodine used in nuclear medicine imaging, including single-photon emission computed tomography (SPECT) or SPECT/CT exams. The isotope's half-life is 13.2230 hours; [1] the decay by electron capture to tellurium-123 emits gamma radiation with a predominant energy of 159 keV (this is the gamma primarily used for imaging). In medical applications, the radiation is detected by a gamma camera. The isotope is typically applied as iodide-123, the anionic form.

Contents

Production

Iodine-123 is produced in a cyclotron by proton irradiation of xenon in a capsule. Xenon-124 absorbs a proton and immediately loses a neutron and proton to form xenon-123, or else loses two neutrons to form caesium-123, which decays to xenon-123. The xenon-123 formed by either route then decays to iodine-123, and is trapped on the inner wall of the irradiation capsule under refrigeration, then eluted with sodium hydroxide in a halogen disproportionation reaction, similar to collection of iodine-125 after it is formed from xenon by neutron irradiation (see article on 125I for more details).

124
Xe
(p,pn) 123
Xe
123
I
124
Xe
(p,2n) 123
Cs
123
Xe
123
I

Iodine-123 is usually supplied as [123
I
]-sodium iodide in 0.1 M sodium hydroxide solution, at 99.8% isotopic purity. [2]

123I for medical applications has also been produced at Oak Ridge National Laboratory by proton cyclotron bombardment of 80% isotopically enriched tellurium-123. [3]

123
Te
(p,n) 123
I

Decay

The detailed decay mechanism is electron capture (EC) to form an excited state of the nearly-stable nuclide tellurium-123 (its half life is so long that it is considered stable for all practical purposes). This excited state of 123Te produced is not the metastable nuclear isomer 123mTe (the decay of 123I does not involve enough energy to produce 123mTe), but rather is a lower-energy nuclear isomer of 123Te that immediately gamma decays to ground state 123Te at the energies noted, or else (13% of the time) decays by internal conversion electron emission (127 keV), [4] followed by an average of 11 Auger electrons emitted at very low energies (50-500 eV). The latter decay channel also produces ground-state 123Te. Especially because of the internal conversion decay channel, 123I is not an absolutely pure gamma-emitter, although it is sometimes clinically assumed to be one.[ citation needed ]

The Auger electrons from the radioisotope have been found in one study to do little cellular damage, unless the radionuclide is directly incorporated chemically into cellular DNA, which is not the case for present radiopharmaceuticals which use 123I as the radioactive label nuclide. The damage from the more penetrating gamma radiation and 127 keV internal conversion electron radiation from the initial decay of 123Te is moderated by the relatively short half-life of the isotope. [5]

Medical applications

Iodine-123
Clinical data
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula 123I
Molar mass 122.91g/mol
3D model (JSmol)
  • [123I-]
  • InChI=1S/HI/h1H/p-1/i1-4
  • Key:XMBWDFGMSWQBCA-AHCXROLUSA-M

123I is the most suitable isotope of iodine for the diagnostic study of thyroid diseases. The half-life of approximately 13.2 hours is ideal for the 24-hour iodine uptake test and 123I has other advantages for diagnostic imaging thyroid tissue and thyroid cancer metastasis. The energy of the photon, 159 keV, is ideal for the NaI (sodium iodide) crystal detector of current gamma cameras and also for the pinhole collimators. It has much greater photon flux than 131I. It gives approximately 20 times the counting rate of 131I for the same administered dose, while the radiation burden to the thyroid is far less (1%) than that of 131I. Moreover, scanning a thyroid remnant or metastasis with 123I does not cause "stunning" of the tissue (with loss of uptake), because of the low radiation burden of this isotope. [6] For the same reasons, 123I is never used for thyroid cancer or Graves disease treatment, and this role is reserved for 131I.

123I is supplied as sodium iodide (NaI), sometimes in basic solution in which it has been dissolved as the free element. This is administered to a patient by ingestion under capsule form, by intravenous injection, or (less commonly due to problems involved in a spill) in a drink. The iodine is taken up by the thyroid gland and a gamma camera is used to obtain functional images of the thyroid for diagnosis. Quantitative measurements of the thyroid can be performed to calculate the iodine uptake (absorption) for the diagnosis of hyperthyroidism and hypothyroidism.

Dosing can vary; 7.5–25 megabecquerels (200–680  μCi ) is recommended for thyroid imaging [7] [8] and for total body while an uptake test may use 3.7–11.1 MBq (100–300 μCi). [9] [10] There is a study that indicates a given dose can effectively result in effects of an otherwise higher dose, due to impurities in the preparation. [11] The dose of radioiodine 123I is typically tolerated by individuals who cannot tolerate contrast mediums containing larger concentration of stable iodine such as used in CT scan, intravenous pyelogram (IVP) and similar imaging diagnostic procedures. Iodine is not an allergen. [12]

Sequence of 123-iodide human scintiscans after an intravenous injection, (from left) after 30 minutes, 20 hours, and 48 hours. A high and rapid concentration of radio-iodide is evident in cerebrospinal fluid (left), gastric and oral mucosa, salivary glands, arterial walls, ovary and thymus. In the thyroid gland, I-concentration is more progressive, as in a reservoir (from 1% after 30 minutes, and after 6, 20 h, to 5.8% after 48 hours, of the total injected dose).(Venturi, 2011) Sequence of 123-iodide total body human scintiscans.jpg
Sequence of 123-iodide human scintiscans after an intravenous injection, (from left) after 30 minutes, 20 hours, and 48 hours. A high and rapid concentration of radio-iodide is evident in cerebrospinal fluid (left), gastric and oral mucosa, salivary glands, arterial walls, ovary and thymus. In the thyroid gland, I-concentration is more progressive, as in a reservoir (from 1% after 30 minutes, and after 6, 20 h, to 5.8% after 48 hours, of the total injected dose).(Venturi, 2011)

123I is also used as a label in other imaging radiopharmaceuticals, such as metaiodobenzylguanidine (MIBG) and ioflupane.

Precautions

Removal of radioiodine contamination can be difficult and use of a decontaminant specially made for radioactive iodine removal is advised. Two common products designed for institutional use are Bind-It [13] and I-Bind.[ citation needed ] General purpose radioactive decontamination products are often unusable for iodine, as these may only spread or volatilize it.[ citation needed ]

See also

Related Research Articles

<span class="mw-page-title-main">Iodine</span> Chemical element, symbol I and atomic number 53

Iodine is a chemical element; it has symbol I and atomic number 53. The heaviest of the stable halogens, it exists at standard conditions as a semi-lustrous, non-metallic solid that melts to form a deep violet liquid at 114 °C (237 °F), and boils to a violet gas at 184 °C (363 °F). The element was discovered by the French chemist Bernard Courtois in 1811 and was named two years later by Joseph Louis Gay-Lussac, after the Ancient Greek Ιώδης, meaning 'violet'.

Radionuclide therapy uses radioactive substances called radiopharmaceuticals to treat medical conditions, particularly cancer. These are introduced into the body by various means and localise to specific locations, organs or tissues depending on their properties and administration routes. This includes anything from a simple compound such as sodium iodide that locates to the thyroid via trapping the iodide ion, to complex biopharmaceuticals such as recombinant antibodies which are attached to radionuclides and seek out specific antigens on cell surfaces.

<span class="mw-page-title-main">Nuclear medicine</span> Medical specialty

Nuclear medicine or nucleology is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear imaging, in a sense, is "radiology done inside out" because it records radiation emitted from within the body rather than radiation that is transmitted through the body from external sources like X-ray generators. In addition, nuclear medicine scans differ from radiology, as the emphasis is not on imaging anatomy, but on the function. For such reason, it is called a physiological imaging modality. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) scans are the two most common imaging modalities in nuclear medicine.

A radioactive tracer, radiotracer, or radioactive label is a synthetic derivative of a natural compound in which one or more atoms have been replaced by a radionuclide. By virtue of its radioactive decay, it can be used to explore the mechanism of chemical reactions by tracing the path that the radioisotope follows from reactants to products. Radiolabeling or radiotracing is thus the radioactive form of isotopic labeling. In biological contexts, experiments that use radioisotope tracers are sometimes called radioisotope feeding experiments.

<span class="mw-page-title-main">Nuclear fission product</span> Atoms or particles produced by nuclear fission

Nuclear fission products are the atomic fragments left after a large atomic nucleus undergoes nuclear fission. Typically, a large nucleus like that of uranium fissions by splitting into two smaller nuclei, along with a few neutrons, the release of heat energy, and gamma rays. The two smaller nuclei are the fission products..

<span class="mw-page-title-main">Scintigraphy</span> Diagnostic imaging test in nuclear medicine

Scintigraphy, also known as a gamma scan, is a diagnostic test in nuclear medicine, where radioisotopes attached to drugs that travel to a specific organ or tissue (radiopharmaceuticals) are taken internally and the emitted gamma radiation is captured by gamma cameras, which are external detectors that form two-dimensional images in a process similar to the capture of x-ray images. In contrast, SPECT and positron emission tomography (PET) form 3-dimensional images and are therefore classified as separate techniques from scintigraphy, although they also use gamma cameras to detect internal radiation. Scintigraphy is unlike a diagnostic X-ray where external radiation is passed through the body to form an image.

<span class="mw-page-title-main">Potassium iodide</span> Ionic compound (KI)

Potassium iodide is a chemical compound, medication, and dietary supplement. It is a medication used for treating hyperthyroidism, in radiation emergencies, and for protecting the thyroid gland when certain types of radiopharmaceuticals are used. In the third world it is also used for treating skin sporotrichosis and phycomycosis. It is a supplement used by people with low dietary intake of iodine. It is administered orally.

<span class="mw-page-title-main">Iodine-131</span> Isotope of iodine

Iodine-131 is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production. It also plays a major role as a radioactive isotope present in nuclear fission products, and was a significant contributor to the health hazards from open-air atomic bomb testing in the 1950s, and from the Chernobyl disaster, as well as being a large fraction of the contamination hazard in the first weeks in the Fukushima nuclear crisis. This is because 131I is a major fission product of uranium and plutonium, comprising nearly 3% of the total products of fission. See fission product yield for a comparison with other radioactive fission products. 131I is also a major fission product of uranium-233, produced from thorium.

<span class="mw-page-title-main">Sodium iodide</span> Chemical compound

Sodium iodide (chemical formula NaI) is an ionic compound formed from the chemical reaction of sodium metal and iodine. Under standard conditions, it is a white, water-soluble solid comprising a 1:1 mix of sodium cations (Na+) and iodide anions (I) in a crystal lattice. It is used mainly as a nutritional supplement and in organic chemistry. It is produced industrially as the salt formed when acidic iodides react with sodium hydroxide. It is a chaotropic salt.

<span class="mw-page-title-main">Pertechnetate</span> Chemical compound or ion

The pertechnetate ion is an oxyanion with the chemical formula TcO
4
. It is often used as a convenient water-soluble source of isotopes of the radioactive element technetium (Tc). In particular it is used to carry the 99mTc isotope which is commonly used in nuclear medicine in several nuclear scanning procedures.

<span class="mw-page-title-main">Isotopes of iodine</span> Nuclides with atomic number of 53 but with different mass numbers

There are 37 known isotopes of iodine (53I) from 108I to 144I; all undergo radioactive decay except 127I, which is stable. Iodine is thus a monoisotopic element.

Iodine-125 (125I) is a radioisotope of iodine which has uses in biological assays, nuclear medicine imaging and in radiation therapy as brachytherapy to treat a number of conditions, including prostate cancer, uveal melanomas, and brain tumors. It is the second longest-lived radioisotope of iodine, after iodine-129.

<span class="mw-page-title-main">Fission products (by element)</span> Breakdown of nuclear fission results

This page discusses each of the main elements in the mixture of fission products produced by nuclear fission of the common nuclear fuels uranium and plutonium. The isotopes are listed by element, in order by atomic number.

<span class="mw-page-title-main">Technetium-99m</span> Metastable nuclear isomer of technetium-99

Technetium-99m (99mTc) is a metastable nuclear isomer of technetium-99, symbolized as 99mTc, that is used in tens of millions of medical diagnostic procedures annually, making it the most commonly used medical radioisotope in the world.

Ioflupane (<sup>123</sup>I) Chemical compound

Ioflupane (123I) is the international nonproprietary name (INN) of a cocaine analogue which is a neuro-imaging radiopharmaceutical drug, used in nuclear medicine for the diagnosis of Parkinson's disease and the differential diagnosis of Parkinson's disease over other disorders presenting similar symptoms. During the DaT scan procedure it is injected into a patient and viewed with a gamma camera in order to acquire SPECT images of the brain with particular respect to the striatum, a subcortical region of the basal ganglia. The drug is sold under the brand name Datscan and is manufactured by GE Healthcare, formerly Amersham plc.

<span class="mw-page-title-main">Iobenguane</span> Chemical compound

Iobenguane, or MIBG, is an aralkylguanidine analog of the adrenergic neurotransmitter norepinephrine (noradrenaline), typically used as a radiopharmaceutical. It acts as a blocking agent for adrenergic neurons. When radiolabeled, it can be used in nuclear medicinal diagnostic and therapy techniques as well as in neuroendocrine chemotherapy treatments.

Nuclear medicine physicians, also called nuclear radiologists or simply nucleologists, are medical specialists that use tracers, usually radiopharmaceuticals, for diagnosis and therapy. Nuclear medicine procedures are the major clinical applications of molecular imaging and molecular therapy. In the United States, nuclear medicine physicians are certified by the American Board of Nuclear Medicine and the American Osteopathic Board of Nuclear Medicine.

<span class="mw-page-title-main">Radioactive iodine uptake test</span>

The radioactive iodine uptake test is a type of scan used in the diagnosis of thyroid problems, particularly hyperthyroidism. It is entirely different from radioactive iodine therapy, which uses much higher doses to destroy cancerous cells. The RAIU test is also used as a follow-up to RAI therapy to verify that no thyroid cells survived, which could still be cancerous.

<span class="mw-page-title-main">Radiopharmaceutical</span> Pharmaceutical drug which emits radiation, used as a diagnostic or therapeutic agent

Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs containing radioactive isotopes. Radiopharmaceuticals can be used as diagnostic and therapeutic agents. Radiopharmaceuticals emit radiation themselves, which is different from contrast media which absorb or alter external electromagnetism or ultrasound. Radiopharmacology is the branch of pharmacology that specializes in these agents.

Iodine is a chemical element with many uses in medicine, depending on the form. Elemental iodine and iodophors are topical antiseptics. Iodine, in non-elemental form, functions as an essential nutrient in human biology. Organic compounds containing iodine are also useful iodinated contrast agents in X-ray imaging.

References

  1. Jun Chen (May–June 2021). "Nuclear Data Sheets for A=123". Nuclear Data Sheets. 174: 1–463. Bibcode:2021NDS...174....1C. doi: 10.1016/j.nds.2021.05.001 . OSTI   1831118. S2CID   236557895.
  2. Nordion, I-123 fact sheet, accessed September 7, 2018
  3. Hupf HB, Eldridge JS, Beaver JE (April 1968). "Production of iodine-123 for medical applications". Int J Appl Radiat Isot. 19 (4): 345–51. doi:10.1016/0020-708X(68)90178-6. PMID   5650883.
  4. Sprawls P (1993). "Radioactive Transitions". The Physical Principles of Medical Imaging (2nd ed.). Aspen Publishers. ISBN   978-0-8342-0309-9.
  5. Narra VR, Howell RW, Harapanhalli RS, Sastry KS, Rao DV (December 1992). "Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design". J. Nucl. Med. 33 (12): 2196–201. PMID   1460515.
  6. Park HM (January 2002). "123I: almost a designer radioiodine for thyroid scanning". J. Nucl. Med. 43 (1): 77–8. PMID   11801707.
  7. "Society of Nuclear Medicine Procedure Guideline for Thyroid Scintigraphy" (PDF). SNMMI. 10 September 2006.
  8. "Radionuclide Thyroid Scans Clinical Guidelines". BNMS. February 2003. Archived from the original on 2017-08-31. Retrieved 2017-08-31.
  9. Venturi, Sebastiano (2011). "Evolutionary significance of iodine". Current Chemical Biology. 5 (3): 155–162. doi:10.2174/187231311796765012. ISSN   1872-3136.
  10. "Society of Nuclear Medicine Procedure Guideline for Thyroid Uptake Measurement" (PDF). SNMMI. 5 September 2006.
  11. Colombetti LG, Johnston AS (1976). "Absorbed radiation dose by the thyroid from radioiodine impurities found in 123I". The International Journal of Applied Radiation and Isotopes. 27 (11): 656–9. doi:10.1016/0020-708X(76)90046-6.
  12. Schabelman E, Witting M (November 2010). "The relationship of radiocontrast, iodine, and seafood allergies: a medical myth exposed". The Journal of Emergency Medicine. 39 (5): 701–707. doi:10.1016/j.jemermed.2009.10.014. PMID   20045605.
  13. "Bind-It Decontamination Products". Laboratory Technologies. 2009.